Reading STRO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track STRO free→Reading STRO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track STRO free→QuarterlyIQ Insights · STRO
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
of this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended (the “ Securities Act ”), except as expressly set forth by specific reference in such a filing.
of this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended (the “ Securities Act ”), except as expressly set forth by specific reference in such a filing.
Termination of a Material Definitive Agreement. As previously disclosed, on April 2, 2021, the Company entered into an Open Market Sale AgreementSM (the “Sales Agreement”) with Jefferies LLC (the “Agent”), pursuant to which the Company could issue and sell, from time to time, shares of its common stock, par value $0.001 per share (the “Common Shares”), up to an aggregate offering price equal to the Maximum Program Amount (the “ATM Program”). On March 23, 2026, the Company and Agent mutually a…
Entry into a Material Definitive Agreement On February 9, 2026, Sutro Biopharma, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell 7,868,383 shares of its common stock (the “Shares”) to the Underwriters (the “Offering”). The Shares will be sold at an offering pri…
Material Modification to the Rights of Security Holders The information set forth in
of this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended (the “ Securities Act ”), except as expressly set forth by specific reference in such a filing.
Costs Associated with Exit or Disposal Activities On September 29, 2025, Sutro Biopharma, Inc. (the “Company”) announced further organizational restructuring to prioritize the advancement of its three preclinical ADC programs and its research and development collaborations. The restructuring is expected to extend the Company’s runway into at least mid-2027 resulting from cost savings associated with the restructuring and certain expected near-term milestone payments. Following further priorit…
of this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended (the “ Securities Act ”), except as expressly set forth by specific reference in such a filing.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 20, 2025, Sutro Biopharma, Inc. (the “Company”) received written notice from The NASDAQ Stock Market, LLC (“NASDAQ”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Global Market, as set forth in Listing Rule 5450(a)(1). In accordance with Listing Rule 5810(c)(3)(A), the Company has a period of 180 calend…
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (c) On June 2, 2025 Sutro Biopharma, Inc. (the “Company”) announced the appointment of Gregory K. Chow as its Chief Financial Officer, principal financial officer and principal accounting officer, effective as of June 2, 2025. Prior to joining the Company, Mr. Chow, age 52, served as Chief Financial and Business Officer of NodThera, a biotechnology company, from August 2024 to March 2025. From January 2024 to Augu…
of this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended (the “ Securities Act ”), except as expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers On April 10, 2025, John Freund, M.D., a member of the Board of Directors (the “Board”) of Sutro Biopharma, Inc., a Delaware corporation (the “Company”) since 2014, informed the Board of his decision to not stand for re-election to the Board. Therefore, Dr. Freund’s term will expire following the Annual Meeting of Shareholders which is scheduled to occur on June 6, 2025. Dr. Freund’s decision not to stand for reelection is not due to any disagreement…
Costs Associated with Exit or Disposal Activities On March 13, 2025, the Company announced the completion of a strategic portfolio review resulting in the prioritization of its three wholly-owned preclinical programs in its next-generation ADC pipeline, beginning with its potentially best-in-class exatecan ADC targeting Tissue Factor, STRO 004, expected to enter the clinic in the second half of 2025. As a result of the reprioritization, the Company announced plans to deprioritize additional i…
of this report, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended (the “Securities Act”), except as expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Chief Executive Officer Separation and Transition Agreement On March 13, 2025, the Company and William J. Newell, the President, Chief Executive Officer (“CEO”) and Director of the Company, entered into a Separation Agreement (the “Newell Separation and Transition Agreement”) following the mutual agreement between the Company’s Board of Directors (t…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.